Date	Firm	Action	Rating
Mar 20, 2014	Morgan Stanley	UPGRADE	Overweight
Nov 13, 2013	Aegis Capital	MAINTAIN	Buy
Aug 15, 2013	Aegis Capital	UPGRADE	Hold → Buy
May 15, 2013	Morgan Stanley	UPGRADE	Underperform → Equal-Weight
Mar 14, 2013	Aegis Capital	MAINTAIN	Hold

Latest Reports

BEARISH 20-F 8/10

Sinovac filed its long-delayed FY2025 annual report (20-F) on June 5, 2026, just days after receiving a Nasdaq delist no

Jun 5, 2026

BEARISH 6-K 7/10

Sinovac Biotech received a Nasdaq delist determination letter on May 22, 2026 for failing to timely file its 2025 Annual

May 29, 2026

∅

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

∅

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

4 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 0 mixed, 1 neutral. Avg impact: 6.0/10.

BEARISH 20-F 8/10

Sinovac filed its long-delayed FY2025 annual report (20-F) on June 5, 2026, just days after receivin

Jun 5, 2026

BEARISH 6-K 7/10

Sinovac Biotech received a Nasdaq delist determination letter on May 22, 2026 for failing to timely

May 29, 2026

NEUTRAL 6-K 2/10

Sinovac extended the deadline for shareholders to submit payment instructions for its previously dec

May 21, 2026

BEARISH 6-K 7/10

Sinovac reported flat revenue of $130.3M for H1 2025, but swung from a $93.9M profit to a $21.7M net

May 8, 2026

∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Analyst Price Targets

Historical data — last covering-analyst action Mar 2014. No current recommendation available.

$3.52 mean target (Mar 2014)

$1.50 Low $6.00 High

Metric	Value
Current Price	$6.47
Target Low	$1.50
Target Mean	$3.52
Target Median	$3.40
Target High	$6.00
# Analysts	6
Recommendation	— (no recent coverage)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2024-07-31	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Next Q 2024-10-31	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Current FY 2024-10-31	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Next FY 2025-10-31	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
+5y	$0.00	$0.00	$0.00	—	—	—	—	—	—
-5y	$0.00	$0.00	$0.00	—	—	—	—	—	—

2 analyst firms have rated this stock: 3 upgrades, 0 downgrades, 1 initiations.

Historical Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
Mar 20, 2014	Morgan Stanley	UPGRADE	—	Overweight
Nov 13, 2013	Aegis Capital	MAINTAIN	—	Buy
Aug 15, 2013	Aegis Capital	UPGRADE	Hold	Buy
May 15, 2013	Morgan Stanley	UPGRADE	Underperform	Equal-Weight
Mar 14, 2013	Aegis Capital	MAINTAIN	—	Hold
Dec 12, 2012	Aegis Capital	INITIATE	—	Hold

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 3, 2026

Clinical Trial

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants

Phase Phase 2 — COMPLETED

May 21, 2026

Clinical Trial

Clinical Trial of PCV24 in Adults Aged ≥18 Years

Phase Phase 2 — COMPLETED

May 21, 2026

clinical_trial_readout

Results Pending: Sinovac Low-dosage PCV24 (Phase 2) — Completed 84d ago

Trial: Clinical Trial of PCV24 in Adults Aged ≥18 Years Sponsor: Sinovac Life Sciences Co., Ltd. Phase: Phase 2 | Completed: 2026-02-26 Conditions: Pn

Apr 21, 2026

clinical_trial_readout

Results Pending: Sinovac Low-dosage PCV24 (Phase 2) — Completed 54d ago

Trial: Clinical Trial of PCV24 in Adults Aged ≥18 Years Sponsor: Sinovac Life Sciences Co., Ltd. Phase: Phase 2 | Completed: 2026-02-26 Conditions: Pn

Mar 30, 2026

Clinical Trial

Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).

Phase Phase 2 — COMPLETED

Mar 30, 2026

clinical_trial_readout

Results Pending: Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell) (Phase 2) — Completed 90d ago

Trial: Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell). Sponsor: Sinovac Biotech Co., Ltd Phase: P